Research & Development
The research and development work of the Global Antibiotic Research and Development Partnership (GARPD) is focused on urgently needed treatments for drug-resistant bacteria on the World Health Organization priority pathogens list, as well as for people disproportionately affected by drug resistance, including babies, children and hospitalized people. GARDP is addressing critically underfunded and unfilled gaps in the development of treatments by tracking, evaluating and contributing where others are not.
Research and development focus
- Clinical development: supporting clinical work from phase 2 trials through to regulatory approval and post-approval evidence.
- Enabling science: non-clinical science activities to support the evaluation and regulatory approval of treatments.
- Formulation and manufacturing: improving drug formulations to ensure affordability, adaptability and effective distribution.
- Regulatory pathways: defining pathways from initial approval to country-level submission through consultation with regulatory authorities and WHO.
- Public health evidence: generating post-approval evidence for policy, guidelines and appropriate clinical use.
- Sustainable access: developing appropriate-use guidance to support the sustainability of new antibiotics.
Research and development pipeline
GARDP’s research and development pipeline outlines our activities and treatment candidates for each of our programmes, from discovery work and clinical trials to registration, access and stewardship. Download the GARDP pipeline by clicking on the graphic below (PDF).
Discovery and exploratory
GARDP’s discovery and exploratory programme focuses on three activities to advance antibiotic R&D – discovery and exploratory research; asset evaluation and development; and external scientific affairs and REVIVE.
Every year 3 million babies and 1.2 million children suffer from sepsis, a life-threatening complication of infection. Three out of every ten neonatal sepsis deaths result from drug-resistant bacteria. GARDP is developing new treatments as well as evidence to the support the use of existing antibiotics for babies and children.
Sexually transmitted infections
Infection rates of gonorrhoea are increasing, with 87 million new cases each year. This infection can lead to infertility and ectopic pregnancy and increases the risk of HIV transmission. Gonorrhoea has progressively developed resistance to available treatments. GARDP is developing a new gonorrhoea treatment.
Serious bacterial infections
Serious bacterial infections are among the major cause of death for people in hospitals. Drug-resistance is making these infections increasingly difficult to treat. GARDP is working on treatments for Gram-negative bacteria, which are the most resistant forms of infections.
“Preventing the very real scenario of a world without effective antibiotics will require particularly enhanced research and development activities. GARDP is ideally placed to build the required partnerships to deliver new treatments for priority public health needs.”
– Anja Karliczek, Federal Research Minister, German Federal Research Ministry of Education and Research